Advanced search    

Search: authors:"Junko Hashimoto"

7 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Reprogramming of the antimycin NRPS-PKS assembly lines inspired by gene evolution

• Google Scholar Search for Shotaro Hoshino in:Nature Research journals • PubMed • Google Scholar Search for Zhijuan Hu in:Nature Research journals • PubMed • Google Scholar Search for Junko Hashimoto

Identification of a gene cluster for telomestatin biosynthesis and heterologous expression using a specific promoter in a clean host

Nakamura Hiroyuki Osada Shunji Takahashi Kazuo Shin-ya Haruo Ikeda Junko Hashimoto Ikuko Kozone Miho Izumikawa OPEN Published: xx xx xxxx Telomestatin, a strong telomerase inhibitor with G-quadruplex

Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats

IBN after withdrawal of PTH. Compliance with Ethical Standards Conflict of interest Satoshi Takeda, Sadaoki Sakai, Keisuke Tanaka, Haruna Tomizawa, Kenichi Serizawa, Kenji Yogo, Junko Hashimoto, Koichi

The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties

Ibandronate is a drug widely used outside Japan for the treatment of osteoporosis. It is available in formulations for intermittent intravenous (i.v.) administration and for intermittent (once monthly) oral administration. Ibandronate was recently approved in Japan as an i.v. injection with a dosing regimen of 1.0 mg once a month. To establish the optimal dose for oral...

Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study

Corp., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teijin Pharma Ltd. Seitaro Yoshida, Junko Hashimoto, Masayuki Matsunaga, and Masato Tobinai are employees of Chugai

Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis

Pharmaceutical Co. Ltd., and Teijin Pharma Ltd. Junko Hashimoto and Masato Tobinai are employees of Chugai Pharmaceutical Co. Ltd. Hideki Mizunuma has received consulting fees from Chugai Pharmaceutical Co. Ltd